Laden... Bitte warten

Company profile

Innate Pharma is a clinical-stage biotechnology company specialized in immuno-oncology and dedicated to improving cancer treatment through innovative therapeutic antibodies that exploit the immune system. Innate Pharma's broad antibody portfolio includes several potential «first-in-class» candidates in clinical and preclinical stages in cancers with high medical need. Innate Pharma is a pioneer in the understanding of NK cell biology and has developed expertise in the tumor microenvironment and tumor antigens, as well as in antibody engineering. Its innovative approach has enabled it to build a diversified proprietary portfolio and to forge alliances with leading biopharmaceutical companies such as Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi as well as a multi-product partnership with AstraZeneca. Revenues break down by source of income as follows:
  • revenues from collaboration and licensing agreements (84.2%);
  • government financing for research expenditure (15.8%).
At the end of 2023, the company had a portfolio of 7 products in clinical development, including 1 in phase III (Monalizumab for the treatment of cancer), 2 in phase II (Lacutamab for the treatment of cutaneous T-cell lymphomas and IPH5201 for the treatment of cancer) and 4 in phase I (IPH5301 for the treatment of solid tumours, IPH6101 for the treatment of relapsed or refractory acute myeloid leukaemia, IPH6401 for the treatment of multiple myeloma and IPH6501 for the treatment of non-Hodgkin lymphoma).

Source: Cofisem - Last Update: 29 Mar 2025
Key Executives
Chairman of the Management Board Jonathan Dickinson
Member of the Management Board Yannis Morel
Chief Operating Officer Yannis Morel
Member of the Management Board Sonia Quaratino
Member of the Management Board Arvind Sood
Chief Financial Officer Frédéric Lombard
Director of Development Nicola Beltraminelli
Chief Human Resources Officer Odile Laurent
General Counsel Claire Saint Blanquat
Chief Communication Officer Henry Wheeler
Head of Investor Relations Henry Wheeler
Source: Cofisem - Last Update: 29 Mar 2025
Key figures
Millenium 2024 2023 2022 2021 2020
Net sales 12.622 51.901 49.580 12.112 56.155
Income from ordinary activities 20.121 51.901 49.580 12.112 56.155
Operating income -51.575 -12.669 -57.425 -47.825 1.079
Cost of financial indebtedness net 640 288 312 341
Equity-accounted companies contribution to income
Net profit from discontinued activities 0 -131 -7.329 -63.155
Net income -49.471 -7.570 -58.103 -52.809 -63.984
Net income (Group share) -49.471 -7.570 -58.103 -52.809 -63.984
Fiscal year end 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards IFRS IFRS IFRS IFRS IFRS
Source: Cofisem - Last Update: 29 Mar 2025
Shareholder information
Other shareholders 67,01 %
Novo Nordisk A/S 12,14 %
MedImmune Limited 9,26 %
Bpifrance Participations 7,90 %
Employees 1,19 %
Members of the board 1,04 %
Mondher Mahjoubi 0,78 %
Managers 0,42 %
Yannis Morel 0,24 %
Group-owned stock 0,02 %
Source: Cofisem - Last Update: 29 Mar 2025

Adresse

Innate Pharma

117 Avenue de Luminy
BP 30191
FR-13009 Marseille
France
Telefonnummer: +33 (0)4 30 30 30 30
https://www.innate-pharma.com/fr
Source: Cofisem - Last Update: 29 Mar 2025

Kontakt

Jérôme Marino
Telefonnummer: +33 (0)4 84 90 31 91
jerome.marino@innate-pharma.fr
Source: Innate Pharma - Last Update: 29 Mar 2025